Pulmonary Stents Market: as the American Association for Bronchology and Interventional Pulmonology and the American Thoracic Society publish the field's first joint clinical practice guideline in the same year that Boston Scientific, Taewoong Medical, and Novatech each expanded their airway stent platforms, interventional pulmonology is graduating from a device-driven specialty into one with a genuine evidence-based standard of care, so stent selection is shifting from individual physician preference toward guideline-anchored decision criteria that favour platforms with the strongest supporting evidence base.

The global pulmonary stents market size was USD 429.7 Million in 2025 and is expected to register a revenue CAGR of 5.2% during the forecast period. Market revenue growth is driven by factors such as rising incidence of malignant central airway obstruction requiring endobronchial stent palliation, covered self-expanding metallic stent platform expansion broadening anatomical coverage for interventional pulmonology programmes, and silicone stent placement technology innovation addressing longstanding deployment accuracy challenges. The first driving factor is rising incidence of malignant central airway obstruction from lung cancer, oesophageal cancer, and mediastinal malignancies, which requires endobronchial stent palliation at interventional pulmonology and thoracic surgery programmes. Self-expanding metallic stents account for the largest single product format share, reflecting this category's centrality to the majority of malignant airway obstruction indications. The second driving factor is covered self-expanding metallic stent platform expansion, as manufacturers extend anatomical size ranges and coverage configurations to address a broader set of central airway obstruction presentations. The third driving factor is silicone stent placement technology innovation, which addresses the longstanding technical challenge of accurate deployment during rigid bronchoscopy silicone stent placement procedures. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single manufacturer's expanded anatomical size range on an already-established covered metallic stent platform converts a narrower set of treatable central airway obstruction presentations into a broader addressable patient population, which lets that manufacturer capture additional procedure volume from interventional pulmonology programmes without requiring an entirely new platform development cycle. Because central airway anatomy varies substantially across patients, particularly at the mainstem bronchial and carina-adjacent tracheal region where malignant obstruction commonly occurs, a manufacturer extending its established platform's size range directly expands the number of patients whose specific anatomical presentation the platform can address, converting an existing validated stent design into a broader addressable procedure population. As a result, demand and revenue share are concentrating around manufacturers with the broadest anatomical size range on already-established, clinically trusted platforms, and the forecast tilts toward these expanded-range platforms rather than manufacturers requiring physicians to adopt entirely new stent designs for atypical anatomical presentations. For instance, in March 2025, Boston Scientific received FDA 510(k) clearance for the WallFlex Pulmonary covered self-expanding nitinol stent in an expanded size range extending from 10 to 24 millimetres diameter and 40 to 140 millimetres length, broadening the platform's anatomical coverage for mainstem bronchial and carina-adjacent tracheal obstruction indications. These are some of the key factors driving revenue growth of the market.

Because both metallic and silicone airway stents remain susceptible to migration and granulation tissue formation at the stent-mucosa interface over extended placement duration, physicians must weigh the palliative benefit of airway patency restoration against the risk of complications requiring stent removal or replacement, which continues to shape stent selection and placement duration decisions.

The technical complexity of silicone stent deployment requiring specialised rigid bronchoscopy expertise is a second constraint, since accurate silicone stent placement, particularly at complex carinal and Y-stent configurations, requires rigid bronchoscopy skill concentrated among a limited number of interventional pulmonology programmes globally, which constrains broader silicone stent adoption regardless of the underlying device's clinical merits.

Reimbursement variability for interventional pulmonology procedures is a third constraint, since coverage for airway stenting procedures varies meaningfully by country and payer, which creates inconsistent adoption incentives even where clinical guidelines support expanded stent use for specific indications.

These factors substantially limit pulmonary stents market growth over the forecast period.

The clearest driver of demand is rising incidence of malignant central airway obstruction from lung cancer, oesophageal cancer, and mediastinal malignancies, which requires endobronchial stent palliation at interventional pulmonology and thoracic surgery programmes. A malignant central airway obstruction that compromises a patient's ability to breathe represents an urgent palliative care need regardless of the underlying cancer's treatability, so stent placement to restore airway patency tracks malignant airway obstruction incidence directly, providing a demand base as structurally predictable as any palliative oncology-adjacent device category. Self-expanding metallic stents account for the largest single product format share, and Taewoong Medical received FDA 510(k) clearance for the NITI-S Pulmonary Covered airway stent in a new biodegradable polyurethane coating formulation designed to facilitate stent retrieval in benign airway stenosis indications by reducing tissue adherence at the stent-mucosa interface. The effect on the market is that baseline pulmonary stent demand remains structurally resilient, providing a stable revenue floor beneath the market's platform-expansion and guideline-development dynamics. These are some of the key factors driving revenue growth of the market.

The second driver is covered self-expanding metallic stent platform expansion, as manufacturers extend anatomical size ranges and coverage configurations to address a broader set of central airway obstruction presentations. Central airway anatomy varies substantially across patients, particularly at the mainstem bronchial and carina-adjacent tracheal region where malignant obstruction commonly occurs, so a manufacturer extending an established platform's size range directly expands the number of patients whose specific anatomical presentation the platform can treat. In March 2025, Boston Scientific received FDA 510(k) clearance for the WallFlex Pulmonary covered self-expanding nitinol stent in an expanded size range extending from 10 to 24 millimetres diameter and 40 to 140 millimetres length, expanding anatomical coverage at US interventional pulmonology programmes treating malignant endobronchial obstruction in large central airway configurations. The effect on the market is that platform-level anatomical breadth is becoming a genuine competitive differentiator among the largest covered metallic stent manufacturers. These are some of the key factors driving revenue growth of the market.

AABIP and ATS published interventional pulmonology's first joint clinical practice guideline in October 2025, the same year Boston Scientific, Taewoong Medical, and Novatech each expanded their airway stent platforms. The specialty is graduating from device-driven practice toward an evidence-anchored standard of care.

The third driver is silicone stent placement technology innovation, which addresses the longstanding technical challenge of accurate deployment during rigid bronchoscopy silicone stent placement, particularly at complex carinal and Y-stent positioning cases. A silicone stent's fixed, non-self-expanding design requires precise positioning at the time of deployment since it cannot be adjusted afterward the way a self-expanding metallic stent can, so a positioning confirmation technology that reduces deployment inaccuracy directly addresses one of the most technically demanding aspects of silicone stent placement. In January 2025, Novatech commercially launched the Dumon ULTRA silicone airway stent with a refined radiopaque marker system enabling fluoroscopic positioning confirmation during rigid bronchoscopy placement without additional bronchoscopic visualisation passes, addressing the primary technical challenge in Dumon-style silicone stent deployment accuracy. The effect on the market is that silicone stent placement technology is becoming more accessible to a broader range of interventional pulmonology programmes, not just the most experienced rigid bronchoscopy specialists. These are some of the key factors driving revenue growth of the market.

However, the pulmonary stents market faces severe adoption constraints from stent migration and granulation tissue formation limiting long-term airway patency, and the technical complexity of silicone stent deployment requiring specialised rigid bronchoscopy expertise concentrated among a limited number of interventional pulmonology programmes.

Because both metallic and silicone airway stents remain susceptible to migration and granulation tissue formation at the stent-mucosa interface over extended placement duration, physicians must weigh the palliative benefit of airway patency restoration against the risk of complications requiring stent removal or replacement, a concern Taewoong Medical's biodegradable retrievability coating specifically targets.

The technical complexity of silicone stent deployment requiring specialised rigid bronchoscopy expertise compounds this, since accurate silicone stent placement, particularly at complex carinal and Y-stent configurations, requires rigid bronchoscopy skill concentrated among a limited number of interventional pulmonology programmes globally, even with positioning aids like Novatech's Dumon ULTRA radiopaque marker system.

Reimbursement variability for interventional pulmonology procedures is the third constraint, since coverage for airway stenting procedures varies meaningfully by country and payer, which creates inconsistent adoption incentives even where the new AABIP/ATS clinical practice guideline supports expanded stent use for specific indications.

These factors substantially limit pulmonary stents market growth over the forecast period.

Based on product type, the global pulmonary stents market is segmented into self-expanding metallic stents, silicone stents, and hybrid covered stents. Self-expanding metallic stents hold the largest revenue share, because their self-expanding deployment mechanism requires less specialised placement expertise than silicone stents, which suits a market where the more broadly deployable format commands the largest revenue category. Silicone stents remain established for benign stenosis and complex Y-stent configurations at experienced rigid bronchoscopy programmes. Hybrid covered stents are expected to register the fastest revenue growth rate in the global pulmonary stents market over the forecast period, driven by Olympus' AERO covered nitinol stent expanding competition in this hybrid category.

Based on material, the global pulmonary stents market is segmented into nitinol, silicone, and biodegradable polymer coating materials. Nitinol holds the largest revenue share, because it is the base material for the majority of covered self-expanding metallic stent platforms, including Boston Scientific's WallFlex Pulmonary and Taewoong Medical's NITI-S families, which ties directly back to the platform expansion dynamics described in the market's primary demand driver. Biodegradable polymer coatings are expected to register the fastest revenue growth rate in the global pulmonary stents market over the forecast period, driven by Taewoong Medical's retrievability-focused coating innovation addressing benign airway stenosis retrieval requirements.

Malignant airway obstruction indication is expected to account for the largest revenue share in the global pulmonary stents market during the forecast period

Based on indication, the global pulmonary stents market is segmented into malignant airway obstruction, benign tracheal or bronchial stenosis, and tracheoesophageal fistula. Malignant airway obstruction holds the largest revenue share, reflecting the volume of palliative stenting cases across lung, oesophageal, and mediastinal cancer indications. Benign tracheal or bronchial stenosis is expected to register the fastest revenue growth rate in the global pulmonary stents market over the forecast period, driven by retrievable stent technology innovation, including Taewoong Medical's biodegradable coating, specifically addressing this indication's requirement for eventual stent removal.

Based on regional analysis, the pulmonary stents market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of interventional pulmonology programme activity and FDA clearance activity creates the deepest and most technologically advanced stent demand globally, and because Boston Scientific, Taewoong Medical, and Novatech all maintain significant commercial presence in the US market. The AABIP and ATS's October 2025 joint clinical practice guideline, published by two US-based professional societies, specifically reinforces the country's role in setting the field's clinical evidence standard. The concentration of FDA clearance activity in the country also means new stent platform generations are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent significant national markets within Europe, anchored by Novatech's French headquarters and Olympus' September 2024 European market entry via CE Mark certification for its AERO covered nitinol stent. The result is steady rather than rapid growth, shaped more by EU MDR compliance requirements than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and South Korea represent two of the largest national markets within the region, anchored by Olympus' Japanese headquarters and Taewoong Medical's South Korean manufacturing base. China's rapidly expanding interventional pulmonology infrastructure leaves considerably more room for growth than in the already stent-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding interventional pulmonology programme capacity driving early stent demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the nitinol alloy and specialised silicone materials that Latin American device distributors depend on, an effect expected to run through 2026 and slow pulmonary stents adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding oncology and thoracic surgery infrastructure and the UAE's regional distribution hubs represent the primary investment centres for pulmonary stents adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional pulmonology infrastructure needed to support advanced stent platforms at scale.